Update on ocular cicatricial pemphigoid and emerging treatments

详细信息    查看全文

• 作者：Munther M. Queisi ; MB^a ; ^b ; Mike Zein ; MB^a ; ^b ; Neerav Lamba ; MD ; MBA^a ; ^b ; Halea Meese ; MS^a ; ^b ; Charles Stephen Foster ; MD^a ; ^b ; ^c ; ^{sfoster@mersi.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：mucus membrane pemphigoid ; ocular cicatricial pemphigoid ; chemotherapy ; alkylating agents ; biologic agents ; immunomodulatory therapy
• 刊名：Survey of Ophthalmology
• 出版年：2016
• 出版时间：May-June 2016
• 年：2016
• 卷：61
• 期：3
• 页码：314-317
• 全文大小：223 K

文摘

Mucous membrane pemphigoid is a systemic disorder that primarily affects mucous membranes. When localized to the conjunctiva, it is known as ocular cicatricial pemphigoid, a potentially blinding disease. Ocular cicatricial pemphigoid is an indication for systemic immunosuppressive treatment to achieve adequate remission. Immunosuppressive agents are selected with a “stepladder” approach, commencing with medications having the fewest side effects. We provide an update of the literature on immunomodulatory agents since 2011 as additional treatment modalities have been explored in the last 4 years.